| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
CURA Stock Overview
Curaleaf Holdings, Inc. operates a cannabis operator in the United States.
Rewards
Risk Analysis
No risks detected for CURA from our risk checks.
Curaleaf Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$6.80 |
| 52 Week High | CA$18.19 |
| 52 Week Low | CA$6.25 |
| Beta | 1.72 |
| 1 Month Change | -12.26% |
| 3 Month Change | -24.61% |
| 1 Year Change | -62.20% |
| 3 Year Change | -26.72% |
| 5 Year Change | n/a |
| Change since IPO | -20.65% |
Recent News & Updates
Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Shareholder Returns
| CURA | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 1.5% | -2.0% | 0.1% |
| 1Y | -62.2% | -71.0% | -2.6% |
Return vs Industry: CURA exceeded the Canadian Pharmaceuticals industry which returned -71% over the past year.
Return vs Market: CURA underperformed the Canadian Market which returned -2.6% over the past year.
Price Volatility
| CURA volatility | |
|---|---|
| CURA Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 11.7% |
| Market Average Movement | 10.0% |
| 10% most volatile stocks in CA Market | 17.3% |
| 10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: CURA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CURA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Matt Darin | https://www.curaleaf.com |
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels.
Curaleaf Holdings Fundamentals Summary
| CURA fundamental statistics | |
|---|---|
| Market Cap | US$3.72b |
| Earnings (TTM) | -US$106.90m |
| Revenue (TTM) | US$1.26b |
3.0x
P/S Ratio-35.0x
P/E RatioIs CURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURA income statement (TTM) | |
|---|---|
| Revenue | US$1.26b |
| Cost of Revenue | US$536.60m |
| Gross Profit | US$725.82m |
| Other Expenses | US$832.72m |
| Earnings | -US$106.90m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 57.49% |
| Net Profit Margin | -8.47% |
| Debt/Equity Ratio | 32.3% |
How did CURA perform over the long term?
See historical performance and comparisonValuation
Is CURA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CURA?
Other financial metrics that can be useful for relative valuation.
| What is CURA's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$3.72b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | 15.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CURA's PS Ratio compare to its peers?
| CURA PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.7x | ||
TRUL Trulieve Cannabis | 2.4x | 12.9% | CA$3.3b |
GTII Green Thumb Industries | 2.2x | 25.3% | CA$2.7b |
CL Cresco Labs | 1x | 17.0% | CA$1.5b |
CRON Cronos Group | 13.4x | 38.2% | CA$1.5b |
CURA Curaleaf Holdings | 3x | 21.3% | CA$4.8b |
Price-To-Sales vs Peers: CURA is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (4.7x).
Price to Earnings Ratio vs Industry
How does CURA's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Sales vs Industry: CURA is expensive based on its Price-To-Sales Ratio (3x) compared to the Canadian Pharmaceuticals industry average (1.9x)
Price to Sales Ratio vs Fair Ratio
What is CURA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3x |
| Fair PS Ratio | 3.5x |
Price-To-Sales vs Fair Ratio: CURA is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).
Share Price vs Fair Value
What is the Fair Price of CURA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CURA (CA$6.8) is trading below our estimate of fair value (CA$115.33)
Significantly Below Fair Value: CURA is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CURA's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Curaleaf Holdings forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Future Growth Score
6/6Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
74.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CURA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: CURA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CURA is expected to become profitable in the next 3 years.
Revenue vs Market: CURA's revenue (21.3% per year) is forecast to grow faster than the Canadian market (7% per year).
High Growth Revenue: CURA's revenue (21.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CURA's Return on Equity is forecast to be high in 3 years time (25.1%)
Discover growth companies
Past Performance
How has Curaleaf Holdings performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-32.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CURA is currently unprofitable.
Growing Profit Margin: CURA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CURA is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare CURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CURA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).
Return on Equity
High ROE: CURA has a negative Return on Equity (-6.43%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Curaleaf Holdings's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CURA's short term assets ($978.0M) exceed its short term liabilities ($436.8M).
Long Term Liabilities: CURA's short term assets ($978.0M) do not cover its long term liabilities ($1.3B).
Debt to Equity History and Analysis
Debt Level: CURA's net debt to equity ratio (18.9%) is considered satisfactory.
Reducing Debt: CURA's debt to equity ratio has increased from 10.1% to 32.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CURA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CURA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is Curaleaf Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CURA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CURA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CURA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CURA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CURA has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.4yrs
Average management tenure
CEO
Matt Darin
0.42
Tenure
Mr. Matthew S. Darin, also known as Matt, served as President of Curaleaf Holdings, Inc since January 04, 2022 until May 09, 2022 and serves as Chief Executive Officer since May 09, 2022. He served as Pres...
Leadership Team
Experienced Management: CURA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
Experienced Board: CURA's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Curaleaf Holdings, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Curaleaf Holdings, Inc.
- Ticker: CURA
- Exchange: CNSX
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$4.801b
- Shares outstanding: 710.14m
- Website: https://www.curaleaf.com
Number of Employees
Location
- Curaleaf Holdings, Inc.
- 301 Edgewater Place
- Suite 405
- Wakefield
- Massachusetts
- 1880
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/28 00:00 |
| End of Day Share Price | 2022/06/28 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.